| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CMO | Chief Medical Officer
2 companies
Joanne M. Donovan is CMO at EWTX, with reported holdings spanning 2 companies. Joanne M. Donovan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $325K at current prices.
Our model assigns Joanne M. Donovan a below-average insider score of 49/100, based on 11 past trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -37.0%.
Joanne M. Donovan's largest disclosed position is in EWTX as CMO, worth about $325K. The EWTX filings lean toward selling, a net 178,176 shares.
Joanne M. Donovan has 26 Form 4 filings on record from June 2015 to August 2026, across 2 companies: CMO at Edgewise Therapeutics (EWTX), 2021–2026; Cmo; SVP Clinical Development at Astria Therapeutics (ATXS), 2015–2020.
The 47 reported transactions were 19 option or other derivative awards, 17 open-market sales, 10 option exercises and 1 conversion.
Counted by filing, the open-market trades come to no purchases and 11 sales worth about $5.7M.
The largest open-market sale was 55,230 shares of EWTX at an average $37.88 on May 5, 2026, about $2.1M.
4 of the 11 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 7 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | EWTX Edgewise Therapeutics, Inc. | CMO | Sale+OE | 9,441 | $43.71 | $412,703.17 | -52.3% | - | - | |
| May 5, 2026 | EWTX Edgewise Therapeutics, Inc. | CMO | Sale+OE | 55,230 | $37.88 | $2,092,062.91 | -92.7% | +1.0% | - | |
| Apr 1, 2026 | EWTX Edgewise Therapeutics, Inc. | CMO | Sale+OE10b5-1 | 28,662 | $32.31 | $926,095.02 | -74.9% | +22.6% | - | |
| Mar 31, 2026 | EWTX Edgewise Therapeutics, Inc. | CMO | Sale+OE10b5-1 | 21,338 | $32.12 | $685,308.28 | -69.0% | +29.9% | - | |
| Mar 27, 2026 | EWTX Edgewise Therapeutics, Inc. | CMO | Sell10b5-1 | 16,358 | $30.98 | $506,734.85 | -63.0% | +35.2% | - | |
| Aug 12, 2025 | EWTX Edgewise Therapeutics, Inc. | CMO | Sale+OE | 2,862 | $13.39 | $38,329.05 | -10.1% | +36.5% | +225.3% | |
| May 2, 2025 | EWTX Edgewise Therapeutics, Inc. | CMO | Sale+OE | 5,187 | $16.45 | $85,347.94 | -19.4% | -15.7% | +81.0% | |
| Jan 28, 2025 | EWTX Edgewise Therapeutics, Inc. | CMO | Sale+OE10b5-1 | 25,000 | $27.63 | $690,657.50 | -60.4% | -43.6% | +3.2% | |
| Sep 20, 2024 | EWTX Edgewise Therapeutics, Inc. | CMO | Sell | 7,162 | $28.29 | $202,602.95 | -33.0% | +8.9% | -49.6% | |
| May 2, 2024 | EWTX Edgewise Therapeutics, Inc. | CMO | Sale+OE | 3,682 | $18.91 | $69,626.62 | -15.6% | -11.7% | -12.3% |